Literature DB >> 17263969

Prospective evaluation of quality of life (SF-36v2) and nonspecific symptoms before and after cure of primary hyperparathyroidism (1-year follow-up).

Cécile Caillard1, Frédéric Sebag, Muriel Mathonnet, Hélène Gibelin, Laurent Brunaud, Coralie Loudot, Jean-Louis Kraimps, Antoine Hamy, Laurent Bresler, Bernard Charbonnel, Joel Leborgne, Jean-François Henry, Jean-Michel Nguyen, Eric Mirallié.   

Abstract

BACKGROUND: Only a minority of patients with primary hyperparathyroidism (pHPT) present with the "classic" symptoms. Most patients have numerous nonspecific symptoms. The aim of this study was to evaluate patients' quality of life and nonspecific symptoms before and after cure for pHPT.
METHODS: This prospective, multicentric study, which took place from May 2003 to September 2004, included 100 patients. Six academic departments of Endocrine Surgery in France participated in the study: the University of Angers, Limoges, Nancy, Nantes, Marseille, and Poitiers. Only cured patients were included. All patients were given preoperative and postoperative questionnaires (the SF-36v2 Health Survey) at 3, 6, and 12 months to evaluate quality of life and nonspecific symptoms.
RESULTS: Preoperatively, the main nonspecific symptoms included the following: anxiety (89%); muscular, bone, or join pain (87%); abdominal distention (82%); forgetfulness (81%); headaches (81%); and mood swings (79%). Quality of life was significantly improved at 3 and 6 months (P < .05). At 1 year postoperatively, statistically significant improvement (P < .05) persisted in all 8 domains of the SF-36v2. At 1 year after parathyroidectomy, 5 symptoms remained significantly improved: appetite loss, weight loss, thirst, headache, and nausea.
CONCLUSIONS: Operative cure of primary hyperparathyroidism significantly improves quality of life and nonspecific symptoms for at least 1 year.

Entities:  

Mesh:

Year:  2007        PMID: 17263969     DOI: 10.1016/j.surg.2006.12.004

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  21 in total

1.  Evaluation of selected cognitive functions before and after surgery for primary hyperparathyroidism.

Authors:  Dominika Babińska; Marcin Barczyński; Tomasz Stefaniak; Tomasz Osęka; Anna Babińska; Dariusz Babiński; Krzysztof Sworczak; Andrzej J Lachiński; Wojciech Nowak; Zbigniew Sledziński
Journal:  Langenbecks Arch Surg       Date:  2011-12-08       Impact factor: 3.445

2.  Persistent symptomatic improvement in the majority of patients undergoing parathyroidectomy for primary hyperparathyroidism.

Authors:  Preethi Gopinath; Gregory P Sadler; Radu Mihai
Journal:  Langenbecks Arch Surg       Date:  2010-07-25       Impact factor: 3.445

3.  Long-term symptom relief from primary hyperparathyroidism following minimally invasive parathyroidectomy.

Authors:  Sebastian R Aspinall; Sam Boase; Peter Malycha
Journal:  World J Surg       Date:  2010-09       Impact factor: 3.352

Review 4.  What symptom improvement can be expected after operation for primary hyperparathyroidism?

Authors:  Nadine R Caron; Janice L Pasieka
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

5.  Timing of symptom improvement after parathyroidectomy for primary hyperparathyroidism.

Authors:  Sara E Murray; Priya R Pathak; David S Pontes; David F Schneider; Sarah C Schaefer; Herbert Chen; Rebecca S Sippel
Journal:  Surgery       Date:  2013-10-04       Impact factor: 3.982

Review 6.  Nontraditional manifestations of primary hyperparathyroidism.

Authors:  Marcella Donovan Walker; Mishaela Rubin; Shonni J Silverberg
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

7.  99mTc-MIBI pinhole SPECT in primary hyperparathyroidism: comparison with conventional SPECT, planar scintigraphy and ultrasonography.

Authors:  Thomas Carlier; Aurore Oudoux; Eric Mirallié; Alain Seret; Isabelle Daumy; Christophe Leux; Caroline Bodet-Milin; Françoise Kraeber-Bodéré; Catherine Ansquer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-25       Impact factor: 9.236

8.  Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism.

Authors:  Claudio Marcocci; Philippe Chanson; Dolores Shoback; John Bilezikian; Laureano Fernandez-Cruz; Jacques Orgiazzi; Christoph Henzen; Sunfa Cheng; Lulu Ren Sterling; John Lu; Munro Peacock
Journal:  J Clin Endocrinol Metab       Date:  2009-05-26       Impact factor: 5.958

9.  Improvement of sleep disturbance and insomnia following parathyroidectomy for primary hyperparathyroidism.

Authors:  Sara E Murray; Priya R Pathak; Sarah C Schaefer; Herbert Chen; Rebecca S Sippel
Journal:  World J Surg       Date:  2014-03       Impact factor: 3.352

10.  Pasieka's parathyroid symptoms scores correlate with SF-36 scores in patients undergoing surgery for primary hyperparathyroidism.

Authors:  Radu Mihai; Gregory P Sadler
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.